FMA
NTLA icon

FNY Managed Accounts’s Intellia Therapeutics NTLA Stock Holding History

FNY Managed Accounts’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,000
Closed -$68.1K – 191
2016
Q3 		$68.1K Buy
+4,000
New +$77.4K 0.06% 181

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

FNY Managed Accounts's NTLA Position: Q4 2016 in Review

FNY Managed Accounts sold out of Intellia Therapeutics (NTLA) in Q4 2016, closing a stake of 4,000 shares — an estimated $68.1K sold.

FNY Managed Accounts first reported a position in NTLA in Q3 2016 and held it in 1 quarter. The position peaked at $68.1K in Q3 2016. 70 funds tracked by Wall St. Rank hold NTLA as of Q4 2016.

  • FNY Managed Accounts reported no remaining Intellia Therapeutics position as of Q4 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 4,000 Intellia Therapeutics shares in Q4 2016, an estimated $68.1K.
  • FNY Managed Accounts first reported a position in Intellia Therapeutics in Q3 2016 and held it in 1 quarter.
  • FNY Managed Accounts's Intellia Therapeutics position peaked at $68.1K in Q3 2016.
  • 70 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2016.

Based on FNY Managed Accounts's 13F filing for Q4 2016, filed 8 Feb 2017.